Nazanin Mousavi, Seyyed Amir Yasin Ahmadi, Z. Mahmoudi, Reza Nekouian, Bijan Ansari-moghaddam, F. Shahsavar
{"title":"Association of FOXP3 Polymorphisms with Susceptibility to Multiple Sclerosis: A Meta-Analysis on Genetic Association Studies","authors":"Nazanin Mousavi, Seyyed Amir Yasin Ahmadi, Z. Mahmoudi, Reza Nekouian, Bijan Ansari-moghaddam, F. Shahsavar","doi":"10.2174/1875692118666200122163559","DOIUrl":null,"url":null,"abstract":"\n\nOXP3 is a gene related to regulatory T cells existing on chromosome\nX. This meta-analysis, based on genetic association studies, was conducted to investigate\nthe association of FOXP3 polymorphisms with susceptibility to multiple sclerosis\n(MS).\n\n\n\nAll genetic association studies covering both FOXP3 and multiple sclerosis\nterms were searched in PubMed, Web of Science and Google Scholar. The information of\ngenotype frequencies was summarized and results were synthesized through odds ratio\n(OR). Heterogeneity and publication bias were investigated using I2 scale and Begg's funnel\nplot, respectively.\n\n\n\nFor rs3761548 -3279 C/A polymorphism, AA/AY genotypes were a risk factor in\ncomparison to CC/CY genotypes (P =0.022; OR =1.752; 95% confidence interval [CI]\n=1.084-2.830; random). AC genotype was a risk factor in comparison to CC/CY genotypes\n(P =0.004; OR =1.537; 95% CI =1.145-2.062; random) and homozygote genotypes\n(P =0.016; OR =1.216; 95% CI =1.038-1.426; fixed). For rs2232365 -924 G/A polymorphism,\n2 significant associations were found according to a fixed effect model; of course,\nthey did not remain significant in the random effect model.\n\n\n\nAccording to the collected populations, susceptibility to and protection from\nMS are associated with rs3761548 -3279 C/A upstream polymorphism. However, it\nshould be regarded that this association is ethnicity dependent with low effect size.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"3 1","pages":"94-103"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692118666200122163559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
OXP3 is a gene related to regulatory T cells existing on chromosome
X. This meta-analysis, based on genetic association studies, was conducted to investigate
the association of FOXP3 polymorphisms with susceptibility to multiple sclerosis
(MS).
All genetic association studies covering both FOXP3 and multiple sclerosis
terms were searched in PubMed, Web of Science and Google Scholar. The information of
genotype frequencies was summarized and results were synthesized through odds ratio
(OR). Heterogeneity and publication bias were investigated using I2 scale and Begg's funnel
plot, respectively.
For rs3761548 -3279 C/A polymorphism, AA/AY genotypes were a risk factor in
comparison to CC/CY genotypes (P =0.022; OR =1.752; 95% confidence interval [CI]
=1.084-2.830; random). AC genotype was a risk factor in comparison to CC/CY genotypes
(P =0.004; OR =1.537; 95% CI =1.145-2.062; random) and homozygote genotypes
(P =0.016; OR =1.216; 95% CI =1.038-1.426; fixed). For rs2232365 -924 G/A polymorphism,
2 significant associations were found according to a fixed effect model; of course,
they did not remain significant in the random effect model.
According to the collected populations, susceptibility to and protection from
MS are associated with rs3761548 -3279 C/A upstream polymorphism. However, it
should be regarded that this association is ethnicity dependent with low effect size.
期刊介绍:
Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.